Press Releases.

Month Year

Month Year

Investor Alerts

May 16, 2023

Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 11, 2023

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
April 13, 2023

Regulus Therapeutics Announces $15 Million Private Placement of Equity
April 12, 2023

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 23, 2023

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates
February 09, 2023

Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference
January 13, 2023

Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2022

Regulus Therapeutics Announces Resignation of Board Member
November 29, 2022

Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations
November 10, 2022

Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates

Show per page